Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 – February 2022
PLOS One · 2025
DOI: 10.1371/journal.pone.0332645 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Elyse M Miller und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States of Amer…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIAID NIH HHS, NIEHS NIH HHS, North Carolina Department of Health and Human Services.
Abstract (Originalsprache)
Background
Surveillance estimates of SARS-CoV-2 infections over time have relied on mandatory clinician and laboratory reporting. These estimates increasingly underestimated true viral incidence due to asymptomatic infections, variable access to testing, and self-administered diagnostics. To overcome these limitations, the North Carolina Department of Health and Human Services partnered with academic researchers to conduct three concurrent population-based longitudinal cohort studies in three distinct North Carolina counties to offer more accurate estimates of the incidence, prevalence, and vaccination rates for SARS-CoV-2.
Methods
We enrolled and followed adult residents of three North Carolina counties from August 2020-February 2022. Demographic and health information was collected in biweekly surveys. Nasal swabs were collected biweekly and tested for SARS-CoV-2 using PCR testing. Blood samples were collected monthly and tested for antibodies to the SARS-CoV-2 nucleocapsid and spike proteins. We calculated monthly seroprevalence, sero-incidence, PCR test positivity, and vaccination uptake.
Results
We enrolled 646 participants. Routine blood samples and nasal swab samples were contributed by 639 and 642 participants, respectively. By February 2022, 98% (95% CI: 97.4–98.2) had antibodies to the SARS-CoV-2 spike protein, and 13% (95% CI: 12.4–14.2) had antibodies to the nucleocapsid protein, indicating viral exposure. PCR testing detected infection among 14% (95% CI: 13.1–15.0) of participants, but cumulative PCR test positivity was only 1.3% (95% CI: 1.2–1.4). Over half of PCR-detected infections were asymptomatic. By February 2022, 97% of participants had completed the primary vaccine series, and 52% had received a booster dose.
Conclusions
Nearly all participants had anti-SARS-CoV-2 antibodies by the end of follow-up, primarily through vaccination. The incidence of PCR-detected infections was similar to antibody testing, but PCR test positivity substantially underestimated incident infections. These findings emphasize the importance of prospective infection monitoring via antibody testing in a comprehensive approach to tracking viral infections in the community setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina, United States of America.
- Institute of Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, United States of America.
- Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, North Carolina, United States of America.
- Division of Cardiology, Duke University, Durham, North Carolina, United States of America.
- Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.
- Duke Clinical and Translational Science Institute, Duke University, Durham, North Carolina, United States of America.
ORCID-Profile: Elyse M Miller, Ross M Boyce, L Kristin Newby, Caitlin A Cassidy, Coralei E Neighbors, Douglas Wixted
Förderung
- NIAID NIH HHS
- NIEHS NIH HHS
- North Carolina Department of Health and Human Services
- National Center for Advancing Translational Sciences
- Claude D. Pepper Older Americans Independence Center, Duke University
- National Institute of Environmental Health Sciences
- David H. Murdock Institute for Business and Culture
Zitieren
APA
Miller, E. M., Boyce, R. M., Kipp, A. M., Newby, L. K., Woods, C. W., Cassidy, C. A., Gunderson, A. K., Lea, C. S., Neighbors, C. E., Shook-Sa, B. E., Sloane, R., Starling, A. P., Wambui, D., Wixted, D., Fleischauer, A., & Aiello, A. E. (2025). Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 – February 2022. PLOS One. https://doi.org/10.1371/journal.pone.0332645
Vancouver
Miller EM, Boyce RM, Kipp AM, Newby LK, Woods CW, Cassidy CA, et al. Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 – February 2022. PLOS One. 2025. doi:10.1371/journal.pone.0332645
BibTeX
@article{Miller2025,
author = {Miller, Elyse M and Boyce, Ross M and Kipp, Aaron M and Newby, L Kristin and Woods, Christopher W and Cassidy, Caitlin A and Gunderson, Annika K and Lea, C Suzanne and Neighbors, Coralei E and Shook-Sa, Bonnie E and Sloane, Richard and Starling, Anne P and Wambui, David and Wixted, Douglas and Fleischauer, Aaron and Aiello, Allison E},
title = {Incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in North Carolina from December 2020 – February 2022},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0332645}
}
EUVIMED